Table 1.
Demographic and clinical characteristics of GBM cases
| Characteristics | Total (n = 40,138) |
Period 1999–2005 (n = 10,932, 27.2%) |
Period 2006–2010 (n = 14,836, 37%) |
Period 2011–2014 (n = 14,370, 35.8%) |
|---|---|---|---|---|
| Age, years ± SD | 64.0 ± 12.4 | 62.4 ± 12.3 | 64.1 ± 12.3 | 65.1 ± 12.4 |
| Age categories | ||||
| 18–49, n (%) | 5455 (13.6) | 1739 (15.9) | 1995 (13.4) | 1721 (12.0) |
| 50–59, n (%) | 7867 (19.6) | 2155 (19.7) | 2899 (19.5) | 2813 (19.6) |
| 60–69, n (%) | 12,396 (30.9) | 3922 (35.9) | 4607 (31.1) | 3867 (26.9) |
| 70–79, n (%) | 11,494 (28.6) | 2587 (23.7) | 4250 (28.6) | 4657 (32.4) |
| ≥ 80, n (%) | 2926 (7.3) | 529 (4.8) | 1085 (7.3) | 1312 (9.1) |
| Women, n (%) | 17,135 (42.7) | 4694 (42.9) | 6322 (42.6) | 6119 (42.6) |
| Men, n (%) | 23,003 (57.3) | 6238 (57.1) | 8514 (57.4) | 8251 (57.4) |
| Median follow-up time, months (IQR) | 9.0 (4.0–18.0) | 9.0 (4.0–18.0) | 10.0 (4.0–21.0) | 8.0 (4.0–16.0) |
| Survival | ||||
| Median OS, months (95% CI) | 10.0 (9.0–10.0) | 9.0 (9.0–9.0) | 10.0 (10.0–10.0) | 10.0 (10.0–10.0) |
| 2-year survival, % (95% CI) | 19.1 (18.7–19.5) | 16.6 (15.9–17.3) | 20.6 (20.0–21.3) | 19.3 (18.6–20.1) |
| Treatment | ||||
| Surgery, yes n (%) | 21,560/26,215a (82.2) | 5703 (74.0) | 8054 (84.1) | 7803 (87.3) |
| Radiotherapy, yes n (%) | 18,941/25,339a (74.7) | 5381 (71.9) | 6748 (75.5) | 6812 (76.4) |
| Chemotherapy, yes n (%) | 11,075/22,728a (48.7) | 1909 (28.3) | 4606 (54.9) | 4560 (60.0) |
| Immunotherapy, yes n (%) | 88/13,463a (0.6) | 20 (0.4) | 25 (0.5) | 43 (1.1) |
OS – overall survival, SD – standard deviation, IQR – interquartile range, CI – confidence interval
aThe first number is the cases that got the treatment modality (coded as yes), while the second number is the total number of cases with non-missing data for this variable